Literature DB >> 31678829

Drugging the gut microbiota: toward rational modulation of bacterial composition in the gut.

Fernando Altamura1, Corinne F Maurice2, Bastien Castagner3.   

Abstract

The human gastrointestinal tract hosts almost a trillion microorganisms, organized in a complex community known as the gut microbiota, an integral part of human physiology and metabolism. Indeed, disease-specific alterations in the gut microbiota have been observed in several chronic disorders, including obesity and inflammatory bowel diseases. Correcting these alterations could revert the development of such pathologies or alleviate their symptoms. Recently, the gut microbiota has been the target of drug discovery that goes beyond classic probiotic approaches. This short review examines the promises and limitations of the latest strategies designed to modulate the gut bacterial community, and it explores the druggability of the gut microbiota by focusing on the potential of small molecules and prebiotics.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacterial metabolism; Drug discovery; Gut health; Gut microbiota; Prebiotics; Probiotics

Mesh:

Substances:

Year:  2019        PMID: 31678829     DOI: 10.1016/j.cbpa.2019.09.005

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  1 in total

1.  Effects of Zymosan on Short-Chain Fatty Acid and Gas Production in in vitro Fermentation Models of the Human Intestinal Microbiota.

Authors:  Xionge Pi; Zaichun Yu; Xiaoxia Yang; Zhi Du; Wei Liu
Journal:  Front Nutr       Date:  2022-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.